KAT-001 / NewG Lab Pharma - LARVOL DELTA

New G-Lab Pharma's U.S. subsidiary applies for FDA clinical trial 1 and 2a for liver cancer treatment [Google translation] (Newsway) - “With the designation of an orphan drug in the US, we expect 'conditional approval' after phase 2 clinical trial....NewGLab Pharma...has prepared a clinical trial plan for phase 1 and 2a clinical trials for KAT (Ko Anti-cancer Technology), an anticancer drug, as a treatment for liver cancer. 23 that it has been submitted to the FDA....This clinical trial will be conducted simultaneously in the United States and Korea, and it is planned to confirm the safety of KAT as well as its efficacy against liver cancer. In Korea, a separate clinical plan will be submitted to the Ministry of Food and Drug Safety."

New P1 trial • New P2a trial • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology